Table 2a.

Hazard ratios from Cox proportional hazards regression models for each of the study endpoints, non-users of statins at baseline.

	Main Study Endpoints			Exploratory Study Endpoints
	Hard CHD	Stroke	Hard CVD	Heart Failure	Atrial Fibrillation	VTE	Cancer (Any)	All-cause Death
HsCRP ≥ 2 vs < 2 mg/L (Ref)
Model 1	1.05 (0.84, 1.30)	1.45 (1.11, 1.89)	1.20 (1.01, 1.42)	1.24 (0.97, 1.58)	1.06 (0.88, 1.29)	1.56 (1.19, 2.05)	1.22 (1.05, 1.41)	1.21 (1.06, 1.37)
Model 2	1.08 (0.86, 1.36)	1.37 (1.04, 1.81)	1.20 (1.00, 1.43)	1.26 (0.97, 1.62)	1.15 (0.95, 1.41)	1.37 (1.03, 1.81)	1.24 (1.07, 1.44)	1.26 (1.10, 1.44)
Model 3	0.94 (0.74, 1.18)	1.10 (0.83, 1.47)	1.00 (0.83, 1.20)	1.03 (0.79, 1.35)	1.09 (0.88, 1.34)	1.30 (0.97, 1.74)	1.16 (0.99, 1.36)	1.17 (1.02, 1.34)
Model 4	0.90 (0.71, 1.14)	1.14 (0.85, 1.53)	0.98 (0.81, 1.19)	0.95 (0.72, 1.25)	1.03 (0.83, 1.28)	1.14 (0.84, 1.55)	1.13 (0.96, 1.32)	1.17 (1.02, 1.34)

Data presented as hazard ratios from Cox proportional hazards regression models

Model 1 was crude (unadjusted)

Model 2 adjusted for age at baseline, sex, race/ethnicity and education

Model 3 adjusted for the variables in Model 2 plus tobacco use, diabetes, total cholesterol, HDL cholesterol, systolic blood pressure, medication use for hypertension, chronic aspirin use (all assessed at baseline)

Model 4 adjusted for the variables in Model 3 plus waist circumference at baseline

Abbreviations: CHD = coronary heart disease; ASCVD = atherosclerotic cardiovascular disease; HDL = high density lipoprotein; HsCRP = high sensitivity C-reactive protein; VTE = venous thromboembolism